|
APN
APN
Aspen to manufacture influenza medicine
Aspen Pharmacare Holdings Limited
(Incorporated in the Republic of South Africa)
(Registration Number 1985/002935/06)
(Share code APN ISIN: ZAE000066692)
("Aspen")
Johannesburg. Sponsor: Investec Bank Limited
Aspen to manufacture influenza medicine oseltamivir
Aspen (APN), South Africa"s largest listed pharmaceutical company, today
announced that it has reached an agreement with Roche to produce a generic
version of oseltamivir for Africa. This complements Roche"s continued efforts to
increase and speed up availability of the medicine for world wide influenza
pandemic planning. The agreement focuses on providing oseltamivir for pandemic
use to further help to address the needs of governments and other not for profit
organisations in the African sub - continent. Roche will provide technical know
how (technical, pre-clinical and clinical data) to assist Aspen to help them
expedite their production and the registration. The agreement also allows the
supply of Active Pharmaceutical Ingredient (API) from Roche to Aspen.
Stephen Saad, Aspen Group CEO said "This agreement complement"s Aspen"s
continued commitment to turning the tide against infectious diseases in Africa.
The confidence placed in Aspen by Roche, a leading multinational pharmaceutical
manufacturer, further endorses the international approval of Aspen"s quality
manufacturing and it"s ability to provide solutions for the African continent.
This product will be manufactured in Aspen"s Port Elizabeth-based Oral Solid
Dose (OSD) facility which was approved by the US Food and Drug Administration in
2004."
David Reddy, Roche"s Pandemic Taskforce Leader, commented: "We are pleased to
announce the partnership with Aspen as the latest step in our scale-up efforts
to meet the needs of governments in preparing for the potential public health
threat posed by avian influenza. This is another demonstration of Roche"s
commitment to working as a collaborative and responsible partner with
governments and the World Health Organization (WHO) to assist in pandemic
planning".
Aspen Two Last
Whilst Roche remains on schedule to meet all orders from African governments by
early 2007, the collaboration with Aspen will further enhance the supply of
oseltamivir for Africa. The agreement is non-exclusive and will mean that Roche
and other sub-licensees will be able to work on pandemic orders within Africa.
\ends
Issued by: Shauneen Beukes, Shauneen Beukes Communications
Tel: (012) 661-8467
Fax: (088) (012) 6618467
Cell: 082 389 8900
On Behalf Of: Stephen Saad, Aspen Holdings Group Chief Executive
Tel: (031) 580-8602
Cell: 083 303 4833
Gus Attridge, Aspen Holdings Deputy Group Chief Executive
Tel: (031) 580-8604
Cell: 083 628 8813
About Aspen:
Aspen is Africa"s largest pharmaceutical manufacturer and a major supplier of
branded pharmaceutical, healthcare and nutritional products to the southern
African and selected international markets. Aspen is one of the largest generics
manufacturers in the southern hemisphere. Aspen is a leading global player in
generic ARVs.
Aspen is one of the top 20 generic manufacturers worldwide and South Africa"s
number one generic brand. Aspen has pharmaceutical manufacturing facilities
located at three sites in South Africa. The Group produces a vast range of
products including tablets, capsules, liquids, creams and others.
Aspen is listed on JSE Limited (JSE) and has a current market cap in excess of
R15 billion.
Additional information
- WHO: Global influenza programme: www.who.int/csr/disease/influenza/en/
- WHO: Avian flu: www.who.int/mediacentre/factsheets/avian_influenza/en/
Date: 16/05/2006 09:00:09 AM Produced by the JSE SENS Department
| Profile Group (Pty) Ltd. has taken care in preparing all information on this website, but does not accept any liability for errors or out-of-date information. | |||||||||||||
| Other Profile Group sites: FundsData Online (unit trust data) | Profile Group corporate site | |||||||||||||
| [ Terms of Use | Privacy Policy | PAIA manual | FAQs/Help | Site Map | © Copyright Reserved 2026 ] | |||||||||||||
|
|||||||||||||
